Raymond James Financial Inc. Makes New $3.63 Million Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Raymond James Financial Inc. purchased a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 727,118 shares of the biotechnology company's stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned 1.22% of Aldeyra Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in shares of Aldeyra Therapeutics by 55.6% during the fourth quarter. Renaissance Technologies LLC now owns 167,100 shares of the biotechnology company's stock worth $834,000 after purchasing an additional 59,700 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in Aldeyra Therapeutics by 114.4% during the 4th quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company's stock worth $3,233,000 after acquiring an additional 345,748 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Aldeyra Therapeutics by 1.9% in the 4th quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock valued at $1,964,000 after buying an additional 7,348 shares during the period. Trexquant Investment LP increased its holdings in shares of Aldeyra Therapeutics by 895.5% in the fourth quarter. Trexquant Investment LP now owns 114,480 shares of the biotechnology company's stock worth $571,000 after acquiring an additional 102,980 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Aldeyra Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock worth $5,588,000 after purchasing an additional 4,927 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This trade represents a 36.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

ALDX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, April 4th. BTIG Research dropped their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Monday, April 7th.

Aldeyra Therapeutics Stock Up 2.4 %

Shares of ALDX stock traded up $0.07 on Friday, reaching $2.78. 309,523 shares of the company were exchanged, compared to its average volume of 726,072. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The company has a 50-day moving average of $4.45 and a 200-day moving average of $4.98. The company has a market cap of $166.21 million, a price-to-earnings ratio of -2.95 and a beta of 0.94. Aldeyra Therapeutics, Inc has a one year low of $1.14 and a one year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30). Analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.